Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Astra beats Roche twice in a day
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
Ultragenyx sees enough in Angelman
The group buys out its partner Genetx, but inconsistent data spook investors.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
Close encounters of the Serd kind
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
